Vincent L. Giranda
Merck & Co., Inc., Rahway, NJ, USA (United States)(US)
Publications by Year
Research Areas
PARP inhibition in cancer therapy, DNA Repair Mechanisms, PI3K/AKT/mTOR signaling in cancer, Cancer therapeutics and mechanisms, Cancer-related Molecular Pathways
Most-Cited Works
- → ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models(2007)764 cited
- → Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies(2009)328 cited
- → Discovering novel ligands for macromolecules using X-ray crystallographic screening(2000)320 cited
- → Discovery of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the Treatment of Cancer(2008)266 cited
- → Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo(2005)244 cited
- → Akt inhibitor A-443654 induces rapid Akt Ser-473 phosphorylation independent of mTORC1 inhibition(2007)169 cited